Pharmaceuticals Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1VRCA Verrica Pharmaceuticals
238.54
(0.03)
 5.64 
(0.19)
2TELO Telomir Pharmaceuticals, Common
211.52
 0.00 
 5.66 
 0.01 
3EOLS Evolus Inc
149.99
 0.08 
 4.83 
 0.41 
4AXSM Axsome Therapeutics
108.44
 0.17 
 4.06 
 0.71 
5AMRX Amneal Pharmaceuticals, Class
86.1
 0.09 
 1.95 
 0.18 
6RDHL Redhill Biopharma
63.66
(0.23)
 4.86 
(1.13)
7LLY Eli Lilly and
53.01
 0.05 
 1.97 
 0.11 
8SCLX Scilex Holding
28.85
(0.10)
 5.52 
(0.53)
9VRNA Verona Pharma PLC
25.83
 0.19 
 3.74 
 0.73 
10PHAT Phathom Pharmaceuticals
25.37
(0.02)
 5.94 
(0.13)
11OPTN OptiNose
24.26
 0.13 
 8.30 
 1.07 
12DRRX Durect
20.5
(0.04)
 3.96 
(0.14)
13BHC Bausch Health Companies
18.78
(0.02)
 2.82 
(0.04)
14HROW Harrow Health
17.45
(0.05)
 4.07 
(0.21)
15LQDA Liquidia Technologies
16.69
 0.19 
 2.60 
 0.49 
16NVO Novo Nordisk AS
16.26
(0.06)
 2.83 
(0.17)
17ETON Eton Pharmaceuticals
15.61
 0.06 
 4.79 
 0.31 
18ZTS Zoetis Inc
15.3
 0.00 
 1.64 
 0.00 
19ITCI Intracellular Th
12.21
 0.17 
 4.81 
 0.82 
20SCPH Scpharmaceuticals
11.31
(0.06)
 2.71 
(0.16)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.